Compelling preclinical study results

Preclinical studies have shown that SUN-101 produces superior anti-tumor activity in human cancer cell lines compared to gemcitabine or nab-paclitaxel, alone or in combination, standard of care chemotherapy drugs used to treat pancreatic cancer.

Sun BioPharma’s novel approach

The Company believes that SUN-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed.  Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life.  Read More
* pancreatic ductal adenocarcinoma

Compound & Clinical Targets

SUN-101

Pancreatic Cancer

Pancreatitis

Leadership

Michael Cullen, MD

Michael Cullen, MD

President and Chairman of the Board
Read More
Cliff McCurdy, Ph.D.

Cliff McCurdy, Ph.D.

Co-Founder, Chief Executive Officer
Read More
Thomas Neenan, Ph.D.

Thomas Neenan, Ph.D.

Chief Scientific Officer
Read More
John E. Allen Jr.

John E. Allen Jr.

Chief Business Officer

Read More

Suzanne Gagnon, MD

Suzanne Gagnon, MD

Chief Medical Officer

Read More

Ajit Shah, Ph.D.

Ajit Shah, Ph.D.

VP Pharmacology

Read More

Andy Kiorpes, Ph.D.

Andy Kiorpes, Ph.D.

Editor-in-Chief of the Journal Toxicology and Industrial Health.
Read More
Cheryl Baker, Ph.D.

Cheryl Baker, Ph.D.

Consultant Cancer Cellular Biology

Read More

Collaborations